Myriad
Illumina to Incorporate Myriad's Genomic Instability Score Into Updated TSO 500 Cancer Assay
GIS measures DNA repair defects via loss of heterozygosity, large-scale state transition, and telomere allele imbalance.
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Premium
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater recognition of such variants.
In Brief This Week: Oncocyte, Lucid Diagnostics, T2 Biosystems, All of Us, Myriad Genetics, More
News items for the week of Nov. 11, 2024
Pharmacogenomics Testing Buoys Myriad Genetics Q3 Revenues While Coverage Remains an Open Question
Premium
Year-over-year pharmacogenomics testing revenues rose 34 percent, but $40 million could be at stake down the road if a decision by UnitedHealthcare goes into effect next year.
Myriad Genetics Stock Tanks After UnitedHealthcare Pulls Coverage of PGx Panels
The payor had been covering Myriad's GeneSight assay since 2019 but has decided there is not enough evidence showing this type of test is medically necessary.